SequelSEC

Theravance Biopharma, Inc. TBPH

Pharmaceutical Preparations · CIK 0001583107 · Fiscal year ends 1231

Revenue
$104.31M
Fiscal year ended 2026-06-30
Operating income
-$4.20M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$448.60MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$8.71Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income4.2×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue4.2×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Net margin98.5%97th
Current ratio10.93x82th
Revenue YoY growth66.9%80th
Operating margin-3.4%78th
R&D / revenue34.8%31th
Effective tax rate18.1%55th
SBC / revenue17.2%45th

Theravance Biopharma, Inc. (TBPH) reported revenue of $104.31M and net income of $53.81M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Theravance Biopharma, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Theravance Biopharma, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$104.31M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$4.20M
Net income$53.81M
Research & development$26.01M
Weighted-average diluted sharesUnavailable
Pretax income$58.92M
Income tax expense$5.11M
Diluted EPS$1.01
Selling, general & administrative$68.75M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Theravance Biopharma, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$219.77M
Total assets$469.77M
Current assets$416.66M
Total liabilitiesUnavailable
Current liabilities$30.77M
Total equity incl. NCI$289.70M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$652.00K

Cash flow

Theravance Biopharma, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$53.74M
Capital expendituresUnavailable
Investing cash flow-$107.47M
Financing cash flow-$8.44M
Net change in cash-$62.16M
Stock-based compensation$19.55M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Theravance Biopharma, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-4.0%
FCF marginUnavailable
SBC / revenue18.7%
Current ratio13.54x
Revenue YoY growth35.1%
Net margin51.6%
R&D / revenue24.9%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rate8.7%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TBPH in the interactive workspace to inspect any figure back to its filing.

Source filings

25-NSE · Filed 2026-09-23View SEC filing
10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-23View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.